Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Curation log — type 1 diabetes

2026-08-28 — Seed

  • Created: INDEX.md (with canonical 17-row Pages table), wiki/overview.md (draft, 34 verified PMIDs), OPEN-QUESTIONS.md (8 seed questions), this log.
  • Searches run (live PubMed, esearch/esummary/efetch + MCP PubMed tools): staging statement (Insel 2015); teplizumab TN-10 and PROTECT; closed-loop pivotal trial and AID meta-analyses; global T1D burden models (Gregory 2022, GBD 2021); Ziegler 2013 autoantibody progression; DCCT 1993 and DCCT/EDIC 30-year follow-up; Rawshani mortality series; Livingstone life expectancy; T1D Exchange registry; time-in-range consensus; zimislecel stem-cell islets; verapamil trials (adult + CLVer); tight-control CLVer arm; Fr1da screening; pre-stage-3 monitoring consensus; DKA-at-diagnosis meta-analysis; impaired hypoglycemia awareness; diabetes distress and fear-of-hypoglycemia reviews; ADA Standards of Care 2026 sections.
  • Verification: all cited PMIDs retrieved from live PubMed during this session; abstracts fetched for all quantitative claims. Volume/page details included only where returned by the live query.
  • Next: full build queued per CONDITIONS-ROADMAP.md — build remaining 16 wiki pages, literature layer (BIBLIOGRAPHY, guidelines REGISTRY, STATISTICS, patient-voice), and verify the trials landscape against ClinicalTrials.gov.

2026-08-28 — Full build

  • Built: all 17 canonical wiki pages; preserved and extended the seeded overview and four pre-existing draft pages; all pages remain draft pending a separate audit session.
  • Literature layer: 96-record deduplicated bibliography; five landmark notes (DCCT, Ziegler seroconversion, teplizumab, iDCL closed loop, zimislecel); 15-record guideline registry; 31-row statistics reference; patient-voice method, themes, sources and four live-verified organizations.
  • Live PubMed searches: staging/natural history; global epidemiology, mortality and DKA; human pancreatic pathology, insulitis and β-cell stress; HLA/GWAS/genetic risk scores; enterovirus, vitamin D, diet and microbiome; Fr1da/monitoring; DIAMOND, IMPACT, iDCL, pediatric closed loop and bionic pancreas; teplizumab, rituximab, abatacept, ATG, oral insulin and verapamil; donor-islet and stem-cell replacement; impaired awareness, HARPdoc and glucagon; DCCT/EDIC; distress, eating, transition, stigma and technology disparities; biomarker and guideline topics. All final page PMIDs were re-resolved in a batch E-utilities verification pass.
  • ClinicalTrials.gov v2 searches: T1D condition plus targeted teplizumab, abatacept, rituximab, ATG, oral insulin, zimislecel/VX-880, VX-264, bionic-pancreas, closed-loop and HARPdoc queries. Fifteen returned NCT records were retained across the condition corpus.
  • Public websites fetched: NICE NG17 and NG18; Diabetes UK; T1International; American Diabetes Association; Diabetes Canada. Breakthrough T1D/JDRF, Life for a Child and several regional sites returned access-control errors and were omitted from the verified organization table.
  • Open questions: replaced seed list with OQ-1 through OQ-20 in two tiers and a ten-row “Dots not yet connected” table.
  • Follow-up: run the required fresh-session audit; verify every quantitative claim against abstracts/full text, check all NCT statuses again, expand guideline and patient-organization geographic coverage, and promote only clean pages to curated.
  • Known limitations: page lengths are dense but mostly below the aspirational 150-line target; the bibliography has 95 unique papers rather than the reference condition’s ~350; organization coverage is English-language and high-income weighted. No inaccessible organization or unreturned identifier was treated as verified.

2026-08-30 — Page-by-page deepening

  • Deepened all 17 canonical wiki pages in place: retained the verified 2026-08-28 text and added quantitative natural-history, incidence, mechanism, screening, biomarker, technology, hypoglycemia, complication, immunotherapy, replacement, guideline, psychosocial, patient-experience, and acute-safety evidence. Final page lengths are 150–210 lines; every page contains at least 25 unique PMID citations (range 25–41).
  • Evidence emphasis: added landmark and confirmatory cohorts, effect sizes with confidence intervals, assay and threshold limitations, adult-versus-child calibration, contemporary comparator problems, intervention nonresponse, harms, implementation inequity, patient-reported outcomes, and explicit tables preserving conflicting interpretations.
  • Live PubMed verification: ran topic searches and record retrieval through PubMed E-utilities on 2026-08-30. The canonical wiki set now contains 256 unique PMIDs. A reconciliation check found zero wiki PMIDs absent from literature/BIBLIOGRAPHY.md; every newly added record has a cited-by mapping.
  • Live ClinicalTrials.gov verification: fetched all 15 NCT records used in the condition through the v2 API on 2026-08-30. Statuses at retrieval were: completed — NCT00279305, NCT00505375, NCT01030861, NCT01773707, NCT02215200, NCT02536950, NCT02940873, NCT03875729; active, not recruiting — NCT03929601, NCT05757713, NCT05791201; recruiting — NCT04786262, NCT06455319, NCT06832410; not yet recruiting — NCT07216391.
  • Literature layers: expanded the statistics file from 31 to 72 table rows; expanded the guideline registry from 15 to 22 records with topic supersession and scope comparison; sharpened OPEN-QUESTIONS.md from 20 to 26 stable questions and from 10 to 15 “dots not yet connected.”
  • Curation state: retained draft status on every wiki page. This was a deepening/build session, not the independent fresh-session audit required for promotion to curated.
  • Remaining limitations: adult prospective staging, general-population screening effectiveness, rare-event safety under modern AID, long-term disease-modification durability, representative patient-experience sampling, and contemporary controlled comparisons for cell replacement remain evidence gaps rather than missing prose.

2026-08-30 — Dedicated citation audit

  • Scope checked: all 17 canonical wiki pages, OPEN-QUESTIONS.md, all 12 Markdown artifacts in literature/, the condition index, and the roadmap entry. The audit inspected 1,580 PMID mentions (1,087 in wiki pages, 416 in literature artifacts, 77 in OPEN-QUESTIONS.md), representing 259 unique PubMed records; 49 NCT mentions representing 16 unique ClinicalTrials.gov records; and eight public URLs (six organizations plus NICE NG17/NG18).
  • Live verification: all 259 current PMIDs resolved in a fresh PubMed E-utilities efetch; 187 linked PMC full texts were additionally retrieved for quantitative cross-checking. All 16 current NCT IDs resolved through exact ClinicalTrials.gov v2 study endpoints. All eight public URLs returned HTTP 200 on recheck. No identifier remained unresolved.
  • Citation errors found and fixed: 32 discrete citation-layer defects — one wrong claim-to-PMID pairing (the ISPAD diabetes-education row incorrectly cited the hypoglycemia chapter), 13 distinct misattributed or bibliographically incorrect records propagated across inline prose/reference lists/bibliography, and 18 stale cited by mappings in BIBLIOGRAPHY.md. Corrections included first authors, publication years, journals, article numbers/pages, and cited-by destinations; the bibliography now reconciles exactly to all 259 records present in the wiki set.
  • Claim corrections and overstatement control: corrected the education evidence row; changed several patient-experience attributions to the actual first authors returned by PubMed; narrowed “technology access” to the insulin-and-device access actually studied; and retained uncertainty around uncontrolled, post hoc, rare-event, and selected-cohort findings. Quantitative claims were checked against abstracts and, where available, PMC full text; no unresolved contradictory number remained.
  • Absence/evidence-gap searches rerun: (1) durable immune tolerance — a newly retrieved six-person “immune education” pilot showed 91–100% baseline C-peptide AUC at 12 months but 44–56% at five years, so the dated gap remains; (2) immune-isolated/hypoimmune replacement — NCT06239636 was found recruiting, establishing human testing but not durable efficacy; (3) vitamin D prevention — a 2025 meta-analysis found no significant reduction in islet autoimmunity or T1D; (4) 2024–2026 ISPAD topic replacements — title/date searches found no replacement for the 2022 insulin, nutrition, hypoglycemia, fasting, or education chapters as of 2026-08-30; (5) previously inaccessible organization sites — Breakthrough T1D and Life for a Child now resolved and were added.
  • Result: all 17 pages meet the required structure and 150–400-line range (150–212), contain 25–41 unique verified PMIDs, have complete body-to-reference coverage, resolve all relative wiki links, and contain zero [unverified] flags. All 17 were promoted to status: curated; INDEX.md now reports audited status and current counts; CONDITIONS-ROADMAP.md was advanced to audited.
  • Remaining flagged: none. Remaining research limitations are stated positively as dated evidence gaps rather than unresolved verification flags. Future audits should recheck fast-moving trial statuses (especially NCT06239636, whose recruiting label was last sponsor-verified in 2024-12), annual ADA/ISPAD supersession, and durability/safety updates for immune and cell-replacement interventions.

2026-10-15 — Periodic literature sweep (Codex; independent audit pending)

  • Window and method: publications dated 2026-08-28 through 2026-10-15 inclusive in PubMed; Europe PMC FIRST_PDATE used the same bounds. Ran 16 major-topic searches each in PubMed, CDSR via PubMed, and Europe PMC: staging; burden; immunopathogenesis; genetics/environment; screening; insulin/technology; immunotherapy; cell replacement; hypoglycemia; complications; psychosocial; guidelines; biomarkers; trials; patient experience/access; safety. Three supplemental PubMed searches covered AACE, inpatient guidance and condition-wide CDSR. Exact queries, PubMed translations, returned IDs and registry checks are in the manifest. The 16 topic searches returned 766 distinct PubMed records before supplemental guideline searches. None of the dated topic-specific or condition-wide CDSR searches returned a record. This is a PubMed/CDSR finding, not an all-database absence; CENTRAL was not searched.
  • Beyond PubMed: Europe PMC returned additional preprints/non-MEDLINE records and full-text availability metadata; none of its no-PMID records survived triage, so no DOI-only citation was added. Crossref was queried for every one of the 13 added records. All lacked PubMed retraction/expression-of-concern publication types; Crossref found no retraction, but correctly identified the adult-consensus correction. The correction was opened: it concerns C-peptide unit labeling and does not change numeric values or conclusions. Full text was read for the screening, adult-care, distress and inpatient-technology guidance, PROTECT PP analysis, and DiAPREV-IT follow-up; PROTECT Table 2 and DiAPREV-IT Table 4 were retrieved. Supporting quotations and table locations are in the manifest.
  • Trial sweep: all 16 previously cited NCT IDs were retrieved through ClinicalTrials.gov v2. Pediatric teplizumab NCT05757713 changed from active/not recruiting to completed (actual completion 2026-08-28; update posted 2026-09-29); platform NCT07216391 changed from not-yet-recruiting to recruiting (update posted 2026-09-09). Neither has posted results. Five tracked records had last-update posting dates in the window; none contains a results section. Six other records have older posted results. No prior results snapshot was available for an outcome-by-outcome historical comparison. NCT04786262 now names both VX-880 and VX-017 in its master-protocol title. NCT06239636 still reports recruiting with sponsor verification from 2024-12; that administrative label is not current operational assurance.
  • Non-US registry boundary: queried WHO ICTRP (HTTP 403), ISRCTN (HTTP 200 cookie/JavaScript gate, no usable search output), EU Clinical Trials Register exact identifiers for pediatric teplizumab and DiAPREV-IT (HTTP 200, no matching legacy records), and the hypoimmune-islet CTIS page (HTTP 200 application shell, no independently readable status). These attempts do not establish absence of regional trials or corroborate ClinicalTrials.gov statuses. SciELO and LILACS could not be searched (documented HTTP 403 access limitation); regional transportability questions remain incompletely searched. Cochrane Library/CENTRAL was not searched because of its documented HTTP 403 block. Unpaywall was skipped because LIFEBANK_CONTACT_EMAIL is unset; no personal email was used or sent to Crossref.
  • Society/statistics/patient sources: retrieved ADA's Standards landing page and ISPAD's guideline index; these still present 2026 ADA and 2024/2022 ISPAD collections. NICE NG17/NG18 fetches returned HTTP 403, so current revision status was not verified. Retrieved T1D Index v3.0 global figures and methods; added three explicitly modeled 2025 portal estimates alongside the 2021 estimates, without claiming a publication/update date within this window or interpreting the difference as an observed trend. Queried Breakthrough T1D US/UK material, Diabetes UK and T1International; Life for a Child news returned HTTP 403. Retained the UK organization's September 28 inpatient-technology/autonomy material in patient-voice sources; no individual patient details were recorded.
  • Triage and changes: 13 bibliography additions: six guideline/consensus documents, the linked adult-consensus correction, PROTECT per-protocol and DiAPREV-IT follow-up analyses, and four bibliography-only records (DIABIL-2, CLOSE IT, HumAn-1 and a teplizumab-associated safety case). The latter four had verified metadata/abstracts and dual retraction checks, but inaccessible full texts; they did not change wiki claims. AACE and Spanish early-stage pathway entries were cataloged without a recommendation synthesis. No landmark note was justified. Updated screening, guidelines, psychosocial, insulin/technology, immunotherapy and trials pages; clarified PP-versus-ITT interpretation and retrospective HLA subgroup limitations. Added two source-table-qualified PROTECT statistics. Sharpened OQ-4/OQ-5 and added OQ-27 on prospective HLA-stratified GAD-alum testing. Updated the index and literature mappings. All changed pages carry 2026-10-15 metadata and remain draft for the separate auditor; no self-promotion to curated.
  • Next sweep: obtain full text for DIABIL-2, CLOSE IT, HumAn-1, the teplizumab/EBV-HLH case, AACE technology guidance and the Spanish pathway before synthesizing outcomes/recommendations. Recheck pediatric teplizumab and the teplizumab/ATG platform for posted results; independently resolve the stale hypoimmune-islet registry through a usable European registry view. Follow immune/cell-replacement durability and safety, genotype-selected prospective prevention, screening uptake/retention/equity, adult staging, ADA 2027/ISPAD supersession, and NICE updates. Reconcile organization-reported renal-treatment developments with primary/regulatory sources before adding claims. Retry blocked non-US and regional sources; absence claims remain source-limited.
  • Delivery boundary: only this condition was edited. No git commands, publication, global generated files or deployment were run, as instructed. Mechanical checks passed: all new PMIDs and all PMID fields in the manifest were resolved via E-utilities; all 13 dual retraction checks passed; reference coverage, YAML dates/statuses and relative links passed. The real public-site mapping/transform was exercised in memory and resolves the manifest to its published path. A full strict MkDocs build was not run because mkdocs is unavailable. These are integrity checks, not the independent substantive audit.

2026-10-22 — Periodic literature sweep

  • Window decision: the assigned window was publications from 2026-08-28 through 2026-10-22. The 2026-10-15 sweep had already incorporated records through 15 October. This sweep re-ran the full window and triaged the 102-PMID delta against the 2026-10-15 manifest, plus trial, guideline, statistics, and patient-organization checks. Bibliography-only near-misses were not added.
  • PubMed: 16 topic searches plus a condition-wide CDSR search, a high-signal publication-type search, retraction searches on both publication date and entry date, a newly indexed search (edat 2026-10-16 to 2026-10-22 with dp from 2026-08-28), and an ISPAD/ADA title search. Topic-union plus supplemental non-retraction IDs: 868. Delta versus the 2026-10-15 manifest: 102 PMIDs, none already in the bibliography. Exact queries, PubMed translations, and ID lists are in the manifest. Tool name lifebank_sweep; no email and no API key were sent.
  • Cochrane: all 16 topic queries and the condition-wide query restricted to "Cochrane Database Syst Rev"[jour] returned count 0 in this date window. That is a PubMed/CDSR finding only. cochranelibrary.com returned HTTP 403, so CENTRAL was not searched.
  • Europe PMC: the same 16 topics were searched with TITLE_ABS:"type 1 diabetes" and FIRST_PDATE:[2026-08-28 TO 2026-10-22]. A non-MEDLINE query (SRC:PPR OR CBA OR CTX OR PAT) returned 57 hits. No record without a PMID was cited. Preprints were not used to change claims.
  • Retraction checks: the existing 272 bibliography PMIDs, in four batches, returned count 0 for retracted publication or expression of concern. Window retraction searches on dp and edat also returned 0. The three records added today are PubMed type Journal Article. A repeat esearch of those three PMIDs against retracted publication and expression of concern returned count 0. Crossref works for 10.1159/hrp/adaag005, 10.1016/j.diabet.2026.101797, and 10.1371/journal.pone.0352531 returned HTTP 200 with no retraction update. The transition DOI has a Crossref is-supplemented-by relation to figshare 10.6084/m9.figshare.33204411; that relation was not treated as a correction or as citable evidence.
  • Records added: PMID 42784528 (de Beaufort; ISPAD/EASD/ADA transition consensus; abstract only; 31 statements not extracted); PMID 42880695 (Metghalchi; TRAKR maternal-antibody transfer; abstract only; fractions labeled abstract-reported and limited to relatives); PMID 42879429 (Burbelo; full text read, including Table 1 and Fig. 3). NICE TA1176 has no PMID: esearch for "technology appraisal"[tiab] AND teplizumab[tiab] returned count 0, so it is cited by URL.
  • Trials: all 16 previously cited NCT IDs were re-fetched from ClinicalTrials.gov v2. Overall status, last-update post date, posted-results flag, and sponsor verification date were unchanged. NCT05757713 and NCT07216391 still have no posted results. NCT06239636 remains RECRUITING with verification 2024-12; its estimated completion of 2025-06 has passed. New registration added: NCT07880769 (VIP-1), not yet recruiting, first posted 2026-10-19, phase 2/3, estimated enrollment 50, stage 1, extended-release verapamil versus placebo, primary outcome a 48-week beta-cell function index. No results and no efficacy claim. ClinicalTrials.gov lists EU CT number 2025-524318-27-00. The CTIS URL for that number returned an application shell, so the European number is cited only as it appears on ClinicalTrials.gov. Discovery since 2026-10-16: 21 records with a last-update post date in range, and 3 first posted in range. The other two first-posted records were not type 1 diabetes trials for this portfolio. NCT07061574 (ATG then adalimumab or verapamil, new onset) was seen and not added: it has no results and is distinct from NCT06455319.
  • Registries outside ClinicalTrials.gov: WHO ICTRP homepage returned HTTP 200, but the direct Trial2 page for NCT07880769 did not render a readable record. ISRCTN remained a cookie/JavaScript gate. The EU Clinical Trials Register teplizumab query returned the search-form shell, not a result list. These attempts do not establish absence of regional trials. SciELO returned HTTP 403. LILACS timed out and returned no result. Neither was searched. Unpaywall was skipped because LIFEBANK_CONTACT_EMAIL is unset. No personal email was sent to Crossref.
  • Guidelines, statistics, and patient organizations: ADA standards page still presents the 2026 Standards and no 2027 edition. ISPAD's current guidelines index still lists 2024, 2022, and 2018 collections. An older ISPAD resource-center URL returned HTTP 404. NICE NG17 was last updated 17 August 2022 and reviewed 30 January 2026, with no recommendation update. NICE NG18 was last updated 11 May 2023 and reviewed 18 December 2025, with no recommendation update. Both pages note Levemir (insulin detemir) discontinuation, anticipated supply end December 2026, and say the impact on recommendations is under assessment. The insulin page does not name detemir, so that notice stays in the registry and this log. NICE TA1176 recommendation 1.1 was read from the live chapter. T1D Index version 3.0 headlines were unchanged: 9,500,194 living with type 1 diabetes in 2025, 513,125 new diagnoses, and 173,516 deaths. The same page also states a missing-people figure and a life-expectancy comparison; those lines were not added to statistics because they belong to the version already cataloged. Breakthrough T1D UK news items of 6 October 2026 and 15 October 2026 are conference roundups and were not added to patient-voice. Organization headlines about tegoprubart, gut bacteria, and draft pregnancy hybrid-closed-loop guidance were not treated as primary sources.
  • Follow-up full text: DIABIL-2 (PMID 42822480), CLOSE IT (PMID 41681122), HumAn-1 (PMID 42409045), AACE technology guidance (PMID 42709002), and the Spanish early-stage pathway (PMID 42760247) remain closed on Europe PMC. The teplizumab/EBV-HLH case (PMID 42520060) is now marked open access (PMC13594791). Its full text was not re-read, and the single case was not used to change a safety claim.
  • Triage exclusions: most of the 102 delta records changed nothing. Reviewed and not added: Smart MDI non-inferiority RCT (PMID 42896857); uncontrolled iLet youth series (PMID 42876070); Spanish T1D-GRS2 validation in a European-ancestry cohort (PMID 42876350); a 22-expert beta-cell preservation statement that is not a society guideline (PMID 42887691); a trial-design commentary (PMID 42900744); a Quest islet-autoantibody ordering trend that does not isolate an approval effect (PMID 42138126); a real-world hybrid closed-loop series (PMID 42897118); a vaccination systematic review that does not supersede Hviid 2004 (PMID 15070789) or Inns 2021 (PMID 34183004) (PMID 42880668); stakeholder and qualitative screening papers (PMID 42895779, PMID 42890530); records without a usable abstract (PMID 42896187, PMID 42891995); preclinical papers; type 2 consensus and CGM papers (PMID 42825450, PMID 42825923, PMID 42878622); and an erratum to an uncited abstract (PMID 42886737). PMID 30000050, a 2006 review titled "Insulin.", appeared inside the date-window ID list and was not cited. No landmark note was written.
  • Pages changed: staging (demoted curated to draft; Burbelo), screening (TRAKR), psychosocial (transition consensus), guidelines (transition consensus, TA1176, NG17/NG18 surveillance), immunotherapy (TA1176 funding boundary), trials (VIP-1 and the unchanged 16-record re-fetch), bibliography, guideline registry, open questions (OQ-1, OQ-2, OQ-12, OQ-18, regional boundary), index, and this log. Statistics and patient-voice were rechecked and not edited. Edited pages stay draft. Nothing was promoted to curated.
  • Next sweep: read the open HLH case before any safety-page change; still obtain full text for DIABIL-2, CLOSE IT, HumAn-1, AACE technology guidance, the Spanish pathway, the transition consensus, and TRAKR before extracting statements or moving fractions into statistics. Recheck NCT05757713 and NCT07216391 for posted results. Resolve NCT06239636 and VIP-1's EU CT number through a readable European registry view. Watch immune and cell-replacement durability, genotype-selected prospective prevention, screening uptake and equity, prospective adult staging, ADA 2027, and any NICE assessment of the Levemir discontinuation. Verify organization-reported tegoprubart and pregnancy hybrid-closed-loop items against primary or regulatory sources before adding them. Retry SciELO, LILACS, CENTRAL, ICTRP, ISRCTN, and EUCTR. A PubMed-only or ClinicalTrials.gov-only absence remains source-limited.
  • Delivery boundary: only type 1 diabetes was edited. No git commands, no .git or .gitignore, no publish, and no hand-edit of WHATS-NEW.md. A full strict MkDocs build was not run.

2026-10-29 — Periodic literature sweep

  • Window decision: PubMed publication dates 2026-08-28 to 2026-10-29. The 2026-10-15 and 2026-10-22 sweeps had already triaged most of that window. The full window was re-run, and triage covered the 101 PMIDs absent from both earlier manifests (915-ID union), plus open follow-ups. Exact queries, translations, IDs, registry results and full-text quotations are in the manifest.
  • PubMed: the same 16 topic searches, run with the extended date bound, returned a 957-PMID union with the supplemental searches. Supplemental searches were a high-signal publication-type search, retractions by dp and by edat 2026-10-23 to 2026-10-29 (both 0), newly indexed records for edat 2026-10-23 to 2026-10-29 (87), and an ISPAD/ADA/consensus title search. Tool lifebank_sweep; no email or API key sent.
  • Cochrane: all 16 topic CDSR queries and the condition-wide CDSR query returned 0. A broader diabetes CDSR query returned one record, PMID 42788405, a protocol for blood-pressure targets in diabetes with no results. It does not supersede or contradict anything here. This is a PubMed/CDSR finding only; CENTRAL could not be searched (cochranelibrary.com HTTP 403).
  • Europe PMC: ran the 16 topic queries (TITLE_ABS:"type 1 diabetes", FIRST_PDATE 2026-08-28 to 2026-10-29). None of the returned PMIDs were missing from the PubMed union. The non-MEDLINE query (PPR/CBA/CTX/PAT) returned 63 records, almost all preprints. None was cited and no preprint changed a claim. Full-text availability was checked for every candidate.
  • Retraction checks: all 275 pre-existing bibliography PMIDs were checked in four batches for Retracted Publication or Expression of Concern; each batch returned 0. The 7 added records and the Klemann case were each checked against PubMed publication types, a per-PMID retraction/EoC esearch (0) and the Crossref updated-by field (empty for all 8). Crossref was called without a mailto. Unpaywall was skipped because LIFEBANK_CONTACT_EMAIL is unset.
  • Records added (7): FINE-ONE primary (Heerspink 2026, PMID 41780000, NEJM). The full text is closed, so figures are abstract-sourced, but the primary result is restated verbatim in the open full text of Beernink 2026 (PMID 42258447, read). Cherney 2026 FINE-ONE eGFR-dip analysis (PMID 42927222, full text read). Berka 2026 Czech Betty general-population screening (PMID 42935169; abstract only; interim counts). Zhang 2026 Swedish parental-autoimmunity cohort (PMID 42931746; abstract only; PubMed lists a PMCID, but PMC returned the "publisher does not allow downloading" stub). Anwar 2023 tegoprubart nonhuman-primate islet study (PMID 37647390), cited only to show that peer-reviewed tegoprubart islet evidence is preclinical. Klein 2026 acmopatide phase 2 (PMID 42949535) is bibliography-only. FINE-ONE and Anwar predate the window. They were retrieved live because an in-window analysis depended on FINE-ONE, and because the 2026-10-15 follow-up asked for organization-reported renal and tegoprubart developments to be checked against primary sources.
  • Follow-up closed: the teplizumab/EBV-HLH case (Klemann 2026, PMID 42520060) was read in full from PMC13594791, with quotations in the manifest. It moved from bibliography-only to the immunotherapy safety section and OQ-1, framed as a single case whose authors state it "cannot prove causality."
  • Trials (ClinicalTrials.gov v2): all 17 tracked records were re-fetched. None changed status, posted-results flag or verification date. NCT07880769's last-update date moved from 10-19 to 10-22 with no status change. NCT05757713 and NCT07216391 still have no results. NCT06239636 is still recruiting with verification dated 2024-12. Added NCT05901831 (FINE-ONE; completed 2025-09; results first posted 2026-10-27) and NCT06305286 (tegoprubart islet transplant; phase 1/2; active, not recruiting; estimated 70; no results). Discovery for 2026-10-23 to 2026-10-29 found 27 records with an update in range and 4 first posted. NCT07891156 (semaglutide lean mass in T1D) and NCT07892651 (MENA/Levant registry) were seen and not added: both are early with no results. NCT06062069 (CT-868) has posted results, matching the acmopatide paper; it is mentioned in the bibliography line only.
  • Registries outside ClinicalTrials.gov: a WHO ICTRP homepage request returned 200, but no programmatic search was attempted. ISRCTN returned a 1.2 KB JavaScript gate. The legacy EUCTR finerenone query returned 9 records, none identifiable as FINE-ONE (heart-failure, type 2 diabetes, empagliflozin-combination and other kidney protocols by title), so FINE-ONE's European registration was not resolved. SciELO returned 403 and LILACS did not respond. None of these establishes absence of regional trials or literature.
  • Guidelines, statistics and organizations: the ADA standards page shows 2027 Scientific Sessions dates only, with no 2027 Standards. ISPAD's home page still lists its consensus guidelines, the 2024 guidelines URL guessed this sweep returned 404, and no 2026 collection was found. NICE NG17 and NG18 dates and the Levemir discontinuation notice are unchanged. TA1176 is unchanged. T1D Index v3.0 headline figures are unchanged. Life for a Child returned 200 this time (403 previously) but had no new dated material. Breakthrough T1D UK posted a 23 October item on a tegoprubart islet/kidney trial and relays earlier conference reports of insulin independence. PubMed had no peer-reviewed human report, and the item gives no NCT number, so it is noted on the trials page as not evidence. Breakthrough T1D US announced a "Roadmap for Disease-Modifying Therapies" publication (22 October); a PubMed title search returned 0, so it is not cited. The NICE pregnancy hybrid-closed-loop item remains organization-reported draft guidance and was not added. REGISTRY, STATISTICS and patient-voice were rechecked and not edited.
  • Triage exclusions (most of the 101): preclinical and engineering papers; case reports; type 2 diabetes, GDM and non-diabetes records retrieved by broad terms; the Knip JAMA Pediatrics commentary (42931744); the Kara Turkish CGM-reimbursement single-center series (42455340); the Chow Hong Kong AID cost-effectiveness model (42910615; IQVIA CORE Diabetes Model, one AID system, trial-derived HbA1c inputs); TransiDEA Italian transition Delphi (42947898), a multi-condition national Delphi not cataloged as a society guideline; the CanScreen T1D needs assessment (42946247; 18 survey responses); TRE pilot (42923036; n=10); obese Chinese children autoantibody prevalence (42619604); Korean ZnT8A (42936974); and the residual β-cell function cohort (42910515; n=72). Three preprints in the PubMed delta were not used. No landmark note was written. FINE-ONE is a candidate once an outcomes trial or full-text access exists, but a 6-month surrogate trial does not meet the bar.
  • Pages changed: complications (FINE-ONE subsection and a new open question; demoted curated → draft), genetics and environmental triggers (Zhang 2026; demoted curated → draft), screening (Betty), disease-modifying immunotherapy (HLH case), clinical-trials landscape (two registrations and the re-fetch note), BIBLIOGRAPHY (282 records), OPEN-QUESTIONS (OQ-1 and OQ-5 sharpened; new OQ-28 on finerenone kidney outcomes; 2026-10-29 regional boundary), INDEX, this log. All changed pages are draft with last-curated 2026-10-29. Nothing was promoted.
  • Next sweep: check whether FINE-ONE's posted ClinicalTrials.gov results differ from the NEJM abstract, and look for any T1D kidney-outcome trial or regulatory label change for finerenone (verify against a primary or regulatory source, not organization news). Obtain full text for Berka (Betty) and Zhang before moving figures into STATISTICS. Look for a peer-reviewed tegoprubart islet report linked to NCT06305286 or another registration. Continue to watch NCT05757713 and NCT07216391 for results. Still outstanding from earlier sweeps: full texts of DIABIL-2, CLOSE IT, HumAn-1, AACE technology guidance, the Spanish pathway, the transition consensus and TRAKR. Also: ADA 2027 Standards (expected around December), ISPAD supersession, NICE action on Levemir, and the stale NCT06239636 status. Consider synthesizing adjunct GLP-1/GIP therapy (acmopatide; NCT07891156) on the insulin page if a phase 3 appears. Retry SciELO, LILACS, ICTRP, ISRCTN and EUCTR; absences remain source-limited.
  • Delivery boundary: only type 1 diabetes was edited. No git commands, no publish, no WHATS-NEW.md edit. A full strict MkDocs build was not run. Mechanical checks passed: all 300 unique PMIDs in the edited files resolved via esummary; every wiki PMID is in BIBLIOGRAPHY.md; every body PMID on the five edited pages appears in its References; all 23 NCT IDs in the edited files resolved via the v2 API; relative links resolve; the manifest parses as JSON; edited pages are 182–203 lines. These are integrity checks, not the independent substantive audit.